Randomized Trial of Ciprofloxacin Doxycycline and Hydroxychloroquine Versus Budesonide in Active Crohn's Disease.

Digestive Diseases and Sciences
Jonathan M RhodesChristopher Probert

Abstract

Increased mucosa-associated E. coli are present in Crohn's disease, but their role in pathogenesis is uncertain. To assess efficacy and safety of an antibiotic/hydroxychloroquine combination effective against E. coli inside macrophages. Adults with moderately active disease (CDAI > 220-450 plus C reactive protein ≥ 5 mg/l and/or fecal calprotectin > 250 μg/g) were randomized to receive (open-label) oral budesonide (Entocort CR 9 mg/day 8 weeks, 6 mg/day 2 weeks, 3 mg/day 2 weeks) or oral ciprofloxacin 500 mg bd, doxycycline 100 mg bd, hydroxychloroquine 200 mg tds for 4 weeks, followed by doxycycline 100 mg bd and hydroxychloroquine 200 mg tds for 20 weeks. Primary endpoints were remission (CDAI ≤ 150) at 10 weeks, remission maintained to 24 weeks, and remission maintained to 52 weeks. Patients not responding (CDAI fall by > 70) by 10 weeks were invited to crossover onto the alternative therapy. Fifty-nine patients were recruited across 8 sites. Including crossover, 39 patients received antibiotics/hydroxychloroquine and 39 received budesonide. At 10 weeks, 24 weeks, and 52 weeks on initial therapy, only 2/27, 2/27, and 1/27 were in remission on antibiotics/hydroxychloroquine compared with 8/32, 1/32, and 1/32 on budesonide (P ...Continue Reading

References

Sep 29, 1994·The New England Journal of Medicine·P RutgeertsH Lorenz-Meyer
Mar 1, 1996·Clinical and Diagnostic Laboratory Immunology·B SendidD Poulain
Feb 12, 2002·Inflammatory Bowel Diseases·George L ArnoldWilliam J Mook
Aug 10, 2004·Gastroenterology·Arlette Darfeuille-MichaudJean-Frédéric Colombel
Aug 17, 2004·The American Journal of Gastroenterology·Paul RyanFergus Shanahan
Dec 12, 2007·Antimicrobial Agents and Chemotherapy·Sreedhar SubramanianBarry J Campbell
Jan 5, 2011·Clinica Chimica Acta; International Journal of Clinical Chemistry·Dirk RoggenbuckKarsten Conrad
Apr 6, 2011·Gut·Craig MowatUNKNOWN IBD Section of the British Society of Gastroenterology
Oct 4, 2011·Bioorganic & Medicinal Chemistry·Oliver SchwardtBeat Ernst
Dec 14, 2011·Gastroenterology·Cosimo PranteraUNKNOWN Retic Study Group (Rifaximin-Eir Treatment in Crohn's Disease)
Aug 16, 2013·The Journal of Antimicrobial Chemotherapy·Jean-Christophe LagierDidier Raoult
Jun 1, 2014·The Journal of Infection·Florence FenollarDidier Raoult
Nov 26, 2014·Journal of Digestive Diseases·Jie Wen SuHong Jie Zhang
Feb 24, 2016·The American Journal of Gastroenterology·Ana GutiérrezRubén Francés
Oct 19, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sonja E van RoedenJan Jelrik Oosterheert
Nov 17, 2017·Gut·Carolina PalmelaJean-Frederic Colombel
Jan 19, 2019·Journal of the Canadian Association of Gastroenterology·M Ellen KuenzigCynthia H Seow
Apr 23, 2019·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Parambir S DulaiWilliam J Sandborn
Feb 2, 2020·Digestive Diseases and Sciences·Akihiko Oka, R Balfour Sartor

❮ Previous
Next ❯

Citations

Sep 4, 2020·Digestive Diseases and Sciences·Jason K Hou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Related Papers

The Cochrane Database of Systematic Reviews
Ali RezaieCynthia H Seow
The Cochrane Database of Systematic Reviews
Eric I BenchimolA Hillary Steinhart
The Cochrane Database of Systematic Reviews
Cynthia H SeowA Hillary Steinhart
© 2021 Meta ULC. All rights reserved